

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**

**廣州銀諾醫藥集團股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 2591)**

**VOLUNTARY ANNOUNCEMENT  
BUSINESS UPDATE ON COMMERCIALISATION OF CORE  
PRODUCT IN MACAU**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”) to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of its recent business updates.

As disclosed in the prospectus of the Company dated 7 August 2025 (the “**Prospectus**”), the Company has been actively pursuing the global expansion of its Core Product (i.e. Efsuabaglutide Alfa), and received BLA (biologics license application) approval of the Core Product for the treatment of type 2 diabetes (T2D) in the Macau Special Administrative Region of the People's Republic of China (“**Macau**”) in June 2025. The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that on 12 September 2025, the first prescription in Macau for the Company's Core Product for the treatment of type 2 diabetes has been issued at Centro Médico HB (華寶醫療中心) in Macau, which signifies the official commencement of commercial sale of the Core Product in Macau.

**Cautionary Statement: The Company cannot guarantee that it will be able to ultimately market the Core Product successfully in Macau. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.**

By order of the Board  
**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**  
**Dr. WANG QINGHUA**  
*Chairman of the Board*

Shanghai, the People's Republic of China, 12 September 2025

*As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.*